MarginsXMarginsX
Home › Markets › Health Care › REGN

Regeneron Pharmaceuticals Inc. (REGN)

REGN trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$952.40
-0.32% on the day
Market cap
$98.5B
Large cap
Revenue · 2025
$14.3B
+1.0% on 2024
Net income · 2025
$4.5B
31.4% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/872589/000087258926000008/0000872589-26-000008-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerREGN on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year1991
SEC CIK0000872589
SEC industry codePharmaceutical Preparations
Incorporated inNY

Financials · 2025

LineValue
Revenue$14.3B
Net income$4.5B
Operating income$3.6B
Net margin31.4%
Operating margin24.9%
Revenue growth+1.0%
Cash$3.1B
Total assets$40.6B
P/E (computed)21.9×
P/S (computed)6.9×

Warning signs

Cash runway
Cash-flow positive
$3.7B cash at September 30, 2026
Share count, 1 year
-1.6%
2025-10-31 to 2026-10-31
Going-concern doubt
No
10-Q filed October 30, 2026
Insider net buying, 12 months
-$12.9M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-10-30
Cash and burn$3.7B cash; operating cash flow $1.2B a quarter.Report 2026-09-30
Shares outstanding103,447,859 (2026-10-31); 105,099,464 a year earlier.Cover page 2026-10-31
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorPricewaterhouseCoopers LLP, Florham Park, New Jersey, United StatesPCAOB Form AP 2026-02-18
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $12.9M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$5.1B$1.9B$1.8B$3.7B$2.0B$16.9B10-Q 2026-10-30
Q2 2026
2026-06-30
$4.3B$1.3B$813.0M$2.5B$2.0B$15.5B10-Q 2026-07-30
Q1 2026
2026-03-31
$3.6B$727.2M$1.1B$3.0B$2.0B$14.9B10-Q 2026-04-29
Q4 2025
2025-12-31
$3.9B$844.6M$1.2B$3.1B$2.0B$14.3B10-K 2026-02-04
Q3 2025
2025-09-30
$3.8B$1.5B$1.6B$2.5B$2.0B$14.2B10-Q 2026-10-30
Q2 2025
2025-06-30
$3.7B$1.4B$1.1B$2.0B$2.0B$14.2B10-Q 2026-07-30
Q1 2025
2025-03-31
$3.0B$808.7M$1.0B$3.1B$2.0B$14.1B10-Q 2026-04-29
Q4 2024
2024-12-31
$3.8B$917.7M$1.3B$2.5B$2.0B$14.2B10-K 2026-02-04

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-3ASR2024-10-31
Latest annual report10-K2026-02-04
Latest quarterly / interim10-Q2026-10-30
Latest current report8-K2026-10-30
Latest proxy
DEFINITIVE ADDITIONAL PROXY SOLICITING MATERIALS
DEFA14A2026-04-24

Source: SEC EDGAR submissions feed, 1,002 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+5.7%
1 month+26.9%
3 months+18.5%
Year to date+23.8%
1 year+37.5%
From 52-week high-1.8%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
GSKGSK plc$50.41-0.08%$102.0B
SNYSanofi ADS$48.39+0.04%$118.0B
BMYBristol-Myers Squibb Company$62.93-0.79%$128.6B
VRTXVertex Pharmaceuticals Incorporated$537.79-0.15%$136.4B
TAKTakeda Pharmaceutical Company Limited$21.59+0.75%$68.2B
PFEPfizer Inc.$28.86-0.10%$164.5B
NVONovo Nordisk A/S$41.60-0.07%$184.2B
ABTAbbott Laboratories$107.45-0.99%$186.1B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier